Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPsychiatry/Behavioral HealthLucet TMS Coverage Update Prior Auth | OpenPayer
    Ask Trek AI about this page
    ModifiedlucetPolicy 20.5.008

    Transcranial Magnetic Stimulation for the Treatment of Major Depression for Florida Blue

    Customize your policy alerts

    Sign up for lucet Policy 20.5.008 alerts

    Get alerted when Policy 20.5.008 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines clinical coverage, authorization requirements, and limitations for TMS treatment of treatment‑resistant major depressive disorder for Florida Blue members; applies to providers requesting TMS benefits under Lucet's administration.

    Policy Summary
    Payerlucet
    PolicyTranscranial Magnetic Stimulation for the Treatment of Major Depression for Florida Blue
    Policy CodePolicy 20.5.008
    Change TypeMinimum age requirement added
    Effective DateFeb 1, 2025
    Next Review Date
    Key ActionSubmit a completed TMS Request Form with evidence of age, standardized rating scale scores meeting thresholds, and documentation of two adequate antidepressant trials (or intolerance) to request prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    Florida Blue requires age to start at 15 years old.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    6 weeks + taperacute course
    15-70age range
    Failure of 2medication trials
    90867/68/69billing codes

    Coverage Criteria

    Initial Authorization

    Covered when ALL of the following are met:

    Initial Authorization: (a) Confirmed diagnosis of severe Major Depressive Disorder WITHOUT psychosis (ICD-10 F32.x or F33.x) with severity documented by one clinically accepted depression rating scale from Table 1; (b) member age 15–70; (c) one of: (i) failure of two adequate trials of FDA‑approved antidepressants from at least two different classes; OR (ii) inability to tolerate adequate trials from at least two different antidepressant classes with documented distinct intolerable side effects; OR (iii) provider judgment that TMS is a less invasive option than ECT for this member or the member declines consent to ECT.see rating scale thresholds in Table 1

    All elements (a)–(c) required

    Retreatment Authorization

    Retreatment covered when ALL of the following are met:

    Retreatment: (1) Member meets all initial authorization requirements for TMS; AND (2) documentation of prior clinical response to a prior TMS course, defined as ≥50% improvement on a standard depression rating scale (Table 1); AND (3) at least 90 days have elapsed since termination of the prior TMS treatment course.≥50% improvement; ≥90 days

    All conditions required

    Delivery & Monitoring

    Covered when ALL of the following delivery and monitoring expectations are met:

    Delivery & Monitoring: (1) TMS is provided using an FDA‑approved or cleared device; (2) initial session including cortical mapping and motor threshold (MT) determination must be personally performed by a board‑certified psychiatrist trained in TMS; subsequent sessions may be administered by the psychiatrist or a certified TMS technician; (3) treatment schedule: one session per day, five days per week for six consecutive weeks, followed by a three‑week taper (week 1 after acute: 3 sessions; week 2: 2 sessions; week 3: 1 session); (4) standardized depression rating scale from Table 1 administered prior to treatment and at least every two weeks during the six‑week course with a final score at the last visit; one consistent scale should be used for the entire course; lack of meaningful change may prompt physician advisor review.session schedule as specified; rating scale frequency as specified

    Psychiatrist must perform first session and MT re‑determination

    Clinical evidence and administrative constraints

    Coverage context and clinical evidence summary from literature (no explicit member-level criteria in this section).

    Evidence summary: Multiple systematic reviews and meta‑analyses report benefit of rTMS/dTMS in treatment‑resistant conditions (including major depression and OCD), but many studies have small sample sizes and limitations; larger, long‑term trials are needed.

    References include meta-analyses and reviews; evidence strength variable [18,20]

    Real-world and duration findings: Real‑world dTMS reports indicate most OCD patients benefit with onset typically within ~20 sessions and continued improvement when extending beyond 29 sessions; maintenance schedules described in reviews as every 2–4 weeks for months to years.

    Supports potential extended/maintenance protocols [21]

    Administrative constraint: age requirement: Policy specifies a minimum age to start TMS of 15 years old.>=15 years

    Document history records this administrative change [36]

    TMS is considered not medically necessary or inappropriate when any of the following exclusionary clinical contexts apply: active substance abuse, active psychotic symptoms, acute suicidal risk, catatonia, severe life‑threatening dysfunction in basic needs, or an active neurologic disorder (examples include encephalopathy, dementia, Parkinson’s disease, post‑stroke syndromes, increased intracranial pressure or bleeding, cerebral aneurysm, arteriovenous malformation, CSF shunts, or implants in the CNS or head/neck).

    Coverage is also excluded for requests that involve non‑TRD psychiatric diagnoses (DSM disorders other than treatment‑resistant major depressive disorder), obsessive–compulsive disorder (OCD), presence of non‑removable metallic objects or implants in the head/neck, Maintenance TMS, Intermittent Theta Burst Stimulation (iTBS), Magnetic Seizure Therapy (MST), and Navigated TMS (nTMS), as these uses are specified as not appropriate in the policy.

    Any request that would require an exception to this medical policy must be submitted for review and approved by the Lucet Chief Medical Officer (CMO) or their designee before coverage will be authorized.

    Requests for Maintenance TMS, iTBS (intermittent theta burst stimulation), MST (magnetic seizure therapy), nTMS (navigated TMS), and TMS for psychiatric diagnoses other than treatment‑resistant depression (including OCD) are considered not medically necessary under this policy and will not be covered.

    The policy review cites systematic reviews and individual studies showing promising symptom reduction with TMS/dTMS across disorders but notes consistent limitations in the evidence base: many studies have small sample sizes, some report mixed results, and prior trials often lack standardized, controlled monitoring of earlier pharmacologic and psychotherapeutic treatments.

    Because of these limitations the literature and the policy highlight a need for larger replication trials and long‑term/maintenance studies to better define durability, optimal protocols, and safety across indications.

    Coding and Rating Scales

    Covered CPT Codes for TMSCPTCovered
    90867E/M with TMS initial service (documented as one unit for initial authorization)
    90868Therapeutic TMS session (36 units for initial authorization)
    90869Therapeutic TMS with cortical mapping or MT re-determination (1 unit initial; additional units require rationale)
    Relevant Diagnosis CodesICD-10
    ICD-10: F32.x, F33.xMajor Depressive Disorder (single and recurrent), without psychosis
    Prior auth affected codes (placeholder)mixed
    affected codesDocument references affected codes in relation to prior authorization (no explicit CPT/HCPCS listed in this part of the document).
    Depression rating scale cutoffs for initial authorization
    Beck Depression Inventory (BDI)Minimum score for initial authorization: >29
    Inventory of Depressive Symptomatology, Clinician-rated (IDS-C)Minimum score for initial authorization: >36
    Quick Inventory of Depressive Symptomatology, Self-report (QIDS-SR)Minimum score for initial authorization: >15
    Montgomery‑Åsberg Depression Rating Scale (MADRS)Minimum score for initial authorization: >34
    Patient Health Questionnaire (PHQ‑9)Minimum score for initial authorization: >19
    Minimum age to start TMS

    Provider Actions & Prior Authorization

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for initial TMS/dTMS treatment courses. Requests must include diagnostic confirmation, a baseline clinically accepted depression rating scale score (see Table 1), patient age (15–70), and documentation of prior medication trials or intolerances. Use the Transcranial Magnetic Stimulation (TMS) Request Form when submitting authorization requests.

    • Required form: Transcranial Magnetic Stimulation (TMS) Request Form
    • Age requirement: 15–70 years
    • Required documentation: depression rating scale score (Table 1), diagnosis (ICD-10 F32.x/F33.x), prior treatment history
    Documentation Required

    Prior Treatment History Expected

    Prior treatment history must be documented. The request should include details of prior pharmacologic and procedural treatments, including dates, agents, doses, durations, outcomes, and any documented intolerances. Specifically, documentation must show failure of two adequate trials of FDA‑approved antidepressants from at least two different classes (or two trials with documented intolerable side effects), unless the provider documents that TMS is being chosen as a less invasive alternative to ECT or the member declines ECT.

    Background & Evidence Summary

    Transcranial Magnetic Stimulation (TMS) is a noninvasive neuromodulation therapy that uses focused magnetic fields delivered to cortical targets to modulate brain activity; it is used primarily as an adjunctive therapy for treatment‑resistant major depressive disorder and has been studied in disorders such as OCD, PTSD, and anxiety disorders.

    Clinical benefits reported in randomized trials and real‑world series include reduction in depressive symptom severity and, in some cases, clinically meaningful response or remission. Common adverse effects are generally mild and transient (for example, scalp discomfort or headache), while procedures such as magnetic seizure therapy carry different risk profiles and are not covered under this policy.

    Policy delivery expectations require use of FDA‑cleared devices, an initial psychiatrist‑performed cortical mapping and motor threshold determination, and standardized rating‑scale monitoring during the acute course. The evidence base for some newer protocols (for example, dTMS, iTBS, MST, and nTMS), specific age groups, and maintenance regimens remains variable, which underlies the policy’s focused coverage for conventional rTMS in treatment‑resistant depression and exclusion of certain protocols and indications.

    Definitions

    TMS — definition of transcranial magnetic stimulation
    DefinitionTranscranial magnetic stimulation (TMS): a noninvasive treatment technique using magnetic fields to influence brain activity.
    SettingDelivered with an FDA‑approved or cleared device in an outpatient clinic setting
    PurposeUsed when other treatment approaches are not effective, primarily for treatment‑resistant major depressive disorder
    TRD (treatment‑resistant depression) — definition used in policy
    DefinitionTreatment‑resistant depression (TRD): severe Major Depressive Disorder without psychosis in a member who has inadequate response or intolerance to trials of antidepressant medications as specified in policy.
    Medication trial requirementMust document failure of two adequate trials of FDA‑approved antidepressants from at least two different classes, or documented intolerance to such trials

    Level of Care Criteria

    Outpatient

    Outpatient TMS is covered when the following level-of-care expectations are met:

    Outpatient Admission: Member has severe Major Depressive Disorder without psychosis (ICD‑10 F32.x/F33.x) meeting rating scale thresholds in Table 1; age between 15 and 70; and meets medication trial or intolerance criteria as required for initial authorization.

    Outpatient TMS framework

    Continued Treatment: Member is receiving TMS according to the prescribed schedule and has standardized rating scales administered at baseline and every two weeks showing clinical progress or a documented clinical rationale for ongoing treatment; lack of meaningful change may trigger physician advisor review.

    Monitoring requirement

    Treatment Modalities

    TMS (rTMS, conventional)

    Standard conventional rTMS (repetitive TMS) is covered when the following modality-specific expectations are met:

    Standard rTMS: Use of FDA‑approved/cleared rTMS devices and established left DLPFC or bilateral protocols as clinically appropriate; initial psychiatrist‑performed cortical mapping and MT determination required; iTBS, MST, and navigated TMS (nTMS) are excluded from coverage unless specifically addressed in future policy updates or exceptions are approved by the Chief Medical Officer.

    Standard rTMS covered with criteria

    TMS / dTMS

    Deep TMS (dTMS) and modality-specific guidance:

    dTMS evidence and use cases: dTMS has been studied and shown efficacy for OCD and has been evaluated for major depression; evidence includes randomized and real‑world studies but is limited by small sample sizes and variable controls—larger replication studies and long‑term evaluations are needed.

    Meta-analyses and real-world reports cited

    Visit Limits and Session Scheduling

    TMS sessions — acute schedule
    Acute scheduleOne session per day, five days per week for six consecutive weeks
    Taper scheduleImmediately after the six‑week period: Week 1 = 3 sessions; Week 2 = 2 sessions; Week 3 = 1 session
    Session monitoringStandardized depression rating scale prior to treatment, then every two weeks during the six‑week period, with a final test at last visit
    TMS sessions (90868) — retreatment
    Retreatment billing unitsRetreatment (repeat acute course) authorized: 36 units of CPT 90868
    Retreatment clinical requirementsRetreatment requires meeting initial treatment requirements, documented prior response (≥50% improvement), and ≥90 days since prior course

    Revision History

    2025-02policy_additionLatest

    Florida Blue (Lucet) added a minimum age requirement specifying that members must be at least 15 years old to start TMS.

    2025-02document_created

    Policy document created/entered as new on 02/2025 by Dr. J. Langlow.

    Policy Summary
    Payerlucet
    PolicyTranscranial Magnetic Stimulation for the Treatment of Major Depression for Florida Blue
    Policy CodePolicy 20.5.008
    Change TypeMinimum age requirement added
    Effective DateFeb 1, 2025
    Next Review Date
    Key ActionSubmit a completed TMS Request Form with evidence of age, standardized rating scale scores meeting thresholds, and documentation of two adequate antidepressant trials (or intolerance) to request prior authorization.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Rating ScalesProvider Actions & Prior AuthorizationBackground & Evidence SummaryDefinitionsLevel of Care CriteriaTreatment ModalitiesVisit Limits and Session SchedulingRevision History
    Minimum age for TMS initiationMember must be between 15 and 70 years of age
    Policy change noteDocument history records new requirement specifying minimum start age of 15 years (02/2025)
    Age documentationAge must be documented in authorization request and clinical record
    • Failure of two trials from at least two antidepressant classes OR two trials with documented intolerable side effects
    • Include dates, doses, duration, and clinical response for each prior trial
    • If prior TMS produced response, include prior rating scale showing ≥50% improvement and date of prior treatment termination (≥90 days since termination for retreatment)
    Prior Authorization

    Exceptions Require CMO Approval

    Exceptions to this policy (including requests that do not meet standard prior authorization criteria) must be submitted for review and require approval by the Lucet Chief Medical Officer (CMO) or their designee. Provide a clear clinical rationale and supporting documentation when requesting an exception.

    • All exceptions require Lucet CMO or designee approval
    • Include detailed clinical rationale and supporting records with exception requests
    • Route exception requests via the TMS Request Form and authorization workflow
    Diagnosis codingICD‑10 codes F32.x or F33.x required for eligibility
    dTMS — definition and context (deep TMS)
    DefinitionDeep transcranial magnetic stimulation (dTMS): a TMS technique designed to stimulate deeper brain regions; studied and shown effective for OCD and evaluated for depression.
    Evidence/contextdTMS has regulatory approvals for OCD and real‑world data report onset of improvement typically within about 20 sessions, with potential benefit beyond 29 sessions
    Typical useConsidered for treatment‑resistant cases where deeper stimulation targets are appropriate; device must be FDA‑approved/cleared
    rTMS — definition and context (repetitive TMS)
    DefinitionRepetitive transcranial magnetic stimulation (rTMS): repeated application of magnetic pulses to modulate cortical activity, used as an adjunctive treatment in treatment‑resistant conditions such as major depression and OCD.
    Evidence/contextMultiple systematic reviews and meta‑analyses suggest add‑on rTMS can reduce symptoms in resistant disorders, though many studies are small and larger trials are needed
    DeliveryAdministered using FDA‑approved/cleared devices with defined protocols (e.g., left DLPFC or bilateral), with initial mapping and motor threshold determination by a psychiatrist
    dTMS delivery note: Typical acute dTMS courses referenced in the literature range from about 20–29 sessions with the possibility to extend based on clinical response; maintenance schedules have been described (e.g., every 2–4 weeks) though controlled data are limited.

    Supports potential extended treatment protocols and maintenance considerations [21]

    Initial authorization noteInitial authorization lists 36 units of 90868 among required billing units for the initial course
    dTMS sessions — typical acute course
    Typical acute coursedTMS acute courses are referenced as typically 20–29 sessions with the possibility to extend beyond 29 sessions for continued benefit
    Onset of improvementReal‑world reports indicate onset of improvement usually occurs within about 20 sessions for OCD
    Maintenance considerationsReviews note maintenance schedules described in literature as every 2–4 weeks for many months or years; further controlled studies needed